A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Trial Profile

A Phase 1a, Randomized, Double-blinded, Placebo-Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ELX-02 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs ELX 02 (Primary)
  • Indications Cystic fibrosis; Cystinosis; Duchenne muscular dystrophy; Inborn genetic disorders; Mucopolysaccharidosis I; Rett syndrome
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Eloxx Pharmaceuticals
  • Most Recent Events

    • 19 Mar 2018 According to an Eloxx Pharmaceutical media release, results from the completed Phase 1 SAD study (NCT02807961 and NCT03292302) will be included in the planned IND and CTA submissions.
    • 13 Feb 2018 Status changed from recruiting to completed.
    • 28 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top